ReviewHuman vaccines & immunotherapeutics2012
Adjuvants for allergy vaccines.
Review in Human vaccines & immunotherapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 60 citations in OpenAlex.
- Adjuvant Strategies to Improve the Efficacy of Allergen Immunotherapy.Journal of inflammation research · 2026Review
- Adverse reactions of rush subcutaneous immunotherapy using standardized house dust mite allergen extract and its prediction model construction and analysis.Asia Pacific allergy · 2025Article
- Novel adjuvants in allergen-specific immunotherapy: where do we stand?Frontiers in immunology · 2024Review
- Thermosensitive PLGA-PEG-PLGA Hydrogel as Depot Matrix for Allergen-Specific Immunotherapy.Pharmaceutics · 2022Article
- [Immunotherapy of allergies: current status].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2020Review
- Immunologic dysfunction contributes to the otitis prone condition.The Journal of infection · 2020Review
- Article
- Mechanisms of Particles in Sensitization, Effector Function and Therapy of Allergic Disease.Frontiers in immunology · 2020Review
- The size of micro-crystalline tyrosine (MCT®) influences its recognition and uptake by THP-1 macrophagesRSC advances · 2019Article
- Microcrystalline Tyrosine and Aluminum as Adjuvants in Allergen-Specific Immunotherapy Protect from IgE-Mediated Reactivity in Mouse Models and Act Independently of Inflammasome and TLR Signaling.Journal of immunology (Baltimore, Md. : 1950) · 2018Article
- Novel vaccines targeting dendritic cells by coupling allergoids to mannan.Allergo journal international · 2018Review
- Adjuvants for allergy immunotherapeutics.Human vaccines & immunotherapeutics · 2017Review
- Neonatal Vaccination: Challenges and Intervention Strategies.Neonatology · 2016Review
- Ever dispense of prescribed allergy medication in children growing up close to traffic: a registry-based birth cohort.BMC public health · 2015Article
- Aluminium in Allergies and Allergen immunotherapy.The World Allergy Organization journal · 2015Article
- Stool microbiota and vaccine responses of infants.Pediatrics · 2014Observational
- Aluminium adjuvants and adverse events in sub-cutaneous allergy immunotherapy.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen-specific immunotherapy is currently performed via either the subcutaneous or sublingual routes as a treatment for type I (IgE dependent) allergies. Aluminum hydroxide or calcium phosphate are broadly used as adjuvants for subcutaneous allergy vaccines, whereas commercial sublingual vaccines rely upon high doses of aqueous allergen extracts in the absence of any immunopotentiator. Adjuvants to be included in the future in products for allergen specific immunotherapy should ideally enhance Th1 and CD4+ regulatory T cell responses. Imunomodulators impacting dendritic or T cell functions to induce IL10, IL12 and IFNγ production are being investigated in preclinical allergy models. Such candidate adjuvants encompass synthetic or biological immunopotentiators such as glucocorticoids, 1,25-dihydroxy vitamin D3, selected probiotic strains (e.g., Lactobacillus and Bifidobacterium species) as well as TLR2 (Pam3CSK4), TLR4 (monophosphoryl lipid A, synthetic lipid A analogs) or TLR9 (CpGs) ligands. Furthermore, the use of vector systems such as mucoadhesive particules, virus-like particles or liposomes are being considered to enhance allergen uptake by tolerogenic antigen presenting cells present in mucosal tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.